arrow
I

Iris Mildenberger

german cancer research center heidelberg
H指数:12
被引数:688

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lomustine with or without procarbazine in recurrent glioblastoma—A propensity score matching analysis

洛莫司汀联合或不联合丙卡巴肼治疗复发胶质母细胞瘤——一项倾向性评分匹配分析

2026-07-310
OA
Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

鞘内注射nivolumab治疗伴软脑膜疾病的转移性实体瘤: 多中心IT-PD1/NOA-26 1期试验的剂量递增部分

2026-06-040
OAAI
End-of-life challenges in neuro-oncological patient care: A survey from the Junge Neuroonkologische Arbeitsgemeinschaft

神经肿瘤患者临终关怀中的挑战:德国青年神经肿瘤学工作组调查

2026-01-010
PRE
EO2401 PEPTIDE IMMUNOTHERAPY plus NIVOLUMAB plus /- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)

EO2401多肽免疫疗法联合纳武利尤单抗及/或贝伐珠单抗治疗首次复发的胶质母细胞瘤:EOGBM1-18 / ROSALIE(NCT04116658)研究中的治疗策略优化(I/II期研究)

2025-11-010
OAAI
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial
2025-09-050
OAAI
CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma

CAR-NK细胞疗法与免疫检查点抑制相结合在胶质母细胞瘤中诱导了NKT细胞反应

2025-03-180
OA
MODULATION OF THE INTRATUMORAL IMMUNE MICROENVIRONMENT BY LOCAL THERAPY WITH NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中,通过用HER2-TARGETED嵌合抗原受体工程化的自然杀伤细胞局部治疗与全身ANTI-PD-1检查点抑制相结合来调节肿瘤内免疫微环境

2024-11-110
PRE
FINAL RESULTS FROM N2M2/NOA-20

N2M2/NOA-20的最终结果

2024-11-110
PRE
FIRST IN HUMAN STUDY OF THE MRNA-BASED CANCER VACCINE CVGBM IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (GBM): FIRST RESULTS FROM THE DOSE ESCALATION PHASE
2024-11-110
PRE
A REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中重复颅内注射单独使用HER2-TARGETED嵌合抗原受体并结合全身ANTI-PD-1检查点抑制的自然杀伤细胞

2024-10-170
PRE
Concurrent gliomas in patients with multiple sclerosis
2023-12-181
OAAI
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
2023-10-192
OAAI
A H3K27M-targeted vaccine in adults with diffuse midline glioma
2023-09-2126
OAAI
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
2023-05-0631
OAAI